Diabetes is a major cardiovascular risk factor, as it significantly increases the risk of cardiovascular events, such as myocardial infarction or stroke. In addition, once these last complications have occurred, the patient prognosis is poorer. Recently, as well documented in the scientific literature, diabetes has been demonstrated to be a significant risk factor for heart failure. New anti-hyperglycemic treatments for Type 2 diabetes and, particularly, sodium-glucose-2 co-transporter inhibitors have reduced cardiovascular events both in primary and secondary prevention. This pharmacological class has been proven to protect Type II diabetes patients from heart failure and to reduce their mortality. These medications’ impact on the occurrence of acute coronary syndromes appears to be more marginal.
Key Words
Type 2 diabetes, cardiovascular complications, SGLT-2 inhibitors